Latham & Watkins advised Seres Therapeutics, while Mayer Brown represented Société des Produits Nestlé on the deal. Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics...
Seres Therapeutics’ VOWST Asset Purchase Agreement With Nestlé Health Science
Otsuka Pharmaceutical’s Acquisition of Jnana Therapeutics
Skadden is advising Otsuka, while Latham & Watkins is advising Jnana on the deal. Nutraceutical and pharmaceutical company Otsuka Holdings Co. Ltd., (Otsuka), announced the definitive...
Foghorn Therapeutics’ $110 Million Common Stock Offering
Ropes & Gray advised Foghorn Therapeutics Inc. on the offering, and Latham & Watkins advised the underwriters. Foghorn Therapeutics Inc. (Nasdaq: FHTX) (“Foghorn”), a clinical-stage biotechnology...
Rhythm Pharmaceuticals’ $150 Million Financing
Latham & Watkins is advising Rhythm Pharmaceuticals on the transaction, and Ropes & Gray is advising Perceptive Advisors LLC. Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (Rhythm), a commercial-stage...
Gurnet Point Capital’s Acquisition of Paratek Pharmaceuticals
Latham & Watkins advises Gurnet Point Capital in acquisition of Paratek Pharmaceuticals. Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of...
Vor Biopharma’s $115.8 Million Common Stock Offering and Private Placement
Latham & Watkins LLP represented the underwriters and placements agents in the transaction. Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced...
Intellia Therapeutics’ $300 Million Common Stock Offering
Goodwin Procter represented Intellia Therapeutics, while Latham & Watkins LLP represented the underwriter in the offering. Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused...
POINT Biopharma’s $125 Million Common Stock Offering
Latham & Watkins represented the underwriters in the offering. POINT Biopharma Global Inc. (NASDAQ: PNT), a company accelerating the discovery, development and global access to life-changing...
MeiraGTx’s Growth Financing Agreement with Perceptive Advisors
Latham & Watkins represented MeiraGTx in the transaction. MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage gene therapy company, announced a financing agreement with affiliates...
Precision BioSciences’ $50 Million Common Stock Offering
Latham & Watkins represented Precision BioSciences, Inc. in the offering. Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR...
Rhythm Pharmaceuticals’ $100 Million Revenue Interest Financing Agreement With HealthCare Royalty Partners
Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq:...
Oscar Health’s $305 Million Convertible Senior Notes Offering
Latham & Watkins represented Oscar Health in the offering. Oscar Health, Inc., the first health insurance company built on a full stack technology platform, has announced a...